Advertisement
New Zealand markets closed
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NZD/USD

    0.5943
    +0.0006 (+0.10%)
     
  • NZD/EUR

    0.5547
    +0.0001 (+0.01%)
     
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • OIL

    82.77
    -0.04 (-0.05%)
     
  • GOLD

    2,330.70
    -7.70 (-0.33%)
     
  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     
  • DAX

    18,088.70
    -48.95 (-0.27%)
     
  • Hang Seng

    17,144.12
    -57.15 (-0.33%)
     
  • NIKKEI 225

    37,882.94
    -577.14 (-1.50%)
     
  • NZD/JPY

    92.3160
    +0.2010 (+0.22%)
     

Can AstraZeneca's COVID Antibody Therapy Win Against Regeneron and Eli Lilly?

AstraZeneca (NASDAQ: AZN) awaits U.S. Emergency Use Authorization for its COVID-19 antibody therapy as a prophylaxis. In this Motley Fool Live video recorded on Oct. 13, Motley Fool contributors Keith Speights and Brian Orelli discuss how effective AstraZeneca might be in competing against antibody therapies marketed by COVID-19 antibody therapies already on the market.